Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ

$4.18

-$0.15 (3.46%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$4.14$4.36

Open $4.34

52 Week Range

$3.79$12.36

Previous Close $4.33

Market Cap1.68B

Volume14.54M

Avg Volume43.35M

P/E (TTM)-2.69

EPS (TTM)$-1.55

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Recursion Pharmaceuticals, Inc.

DEC82025

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Source: GlobeNewsWire•8 days ago

SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investiga...

DEC12025

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Source: GlobeNewsWire•15 days ago

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase...

NOV52025

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Source: GlobeNewsWire•41 days ago

SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its third quarter ended Septemb...

NOV52025

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Source: GlobeNewsWire•41 days ago

Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Office...

NOV42025

Recursion to Participate in Upcoming Investor Conferences

Source: GlobeNewsWire•42 days ago

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Guggen...

OCT282025

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Source: GlobeNewsWire•49 days ago

Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 f...